Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YTH24.5-SG3249
- Development stage
- Preclinical
- Lead developer
- UCL Cancer Institute
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
YTH24.5-SG3249 is a preclinical-stage antibody-drug conjugate (ADC) consisting of the rat IgG2b anti-human CD45 monoclonal antibody clone YTH24.5 conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer payload tesirine (SG3249) via a cathepsin B-cleavable valine-alanine linker. Developed by ADC Therapeutics in collaboration with UCL Great Ormond Street Institute of Child Health, UCL Cancer Institute, and Great Ormond Street Hospital, the ADC targets CD45 (receptor-type tyrosine-protein phosphatase C), which is expressed on almost all cells of the hematopoietic lineage, including hematopoietic stem cells (HSCs) and hematological malignancies. YTH24.5-SG3249 is designed as a targeted conditioning agent for allogeneic stem cell transplantation (SCT) and gene therapy, aiming to ablate host HSCs with minimal non-hematopoietic toxicity, and as a cytoreductive bridge to SCT in patients with refractory leukemia.
- Other names
- YTH24.5-tesirineYTH-24.5-tesirineYTH 24.5-tesirineanti-CD45-SG3249anti-CD-45-SG3249anti-CD 45-SG3249
02
Targets
CD45RA (T-cell surface glycoprotein CD45 isoform RA)
Beyond the preview
Go deeper on YTH24.5-SG3249.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YTH24.5-SG3249.